RU2014145911A - Methods for influencing BRCA2 gene expression - Google Patents
Methods for influencing BRCA2 gene expression Download PDFInfo
- Publication number
- RU2014145911A RU2014145911A RU2014145911A RU2014145911A RU2014145911A RU 2014145911 A RU2014145911 A RU 2014145911A RU 2014145911 A RU2014145911 A RU 2014145911A RU 2014145911 A RU2014145911 A RU 2014145911A RU 2014145911 A RU2014145911 A RU 2014145911A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- brca2 gene
- influencing
- gene
- antisense oligonucleotide
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ воздействия на экспрессию гена BRCA2 в клетках пациента, включающий приведение в контакт указанных клеток с одной или несколькими миРНК, специфичными для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности указанного гена.2. Способ по п. 1, где экспрессию понижают.3. Композиция, содержащая одну или более миРНК, специфичных для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности гена BRCA2.4. Способ лечения заболевания, связанного с геном BRCA2, включающий введение пациенту эффективной дозы одной или нескольких миРНК, специфичных для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности гена BRCA2.1. A method of influencing the expression of the BRCA2 gene in a patient’s cells, comprising contacting said cells with one or more siRNAs specific for an antisense oligonucleotide, with a sequence of at least 70% identical sequence to the specified gene. The method of claim 1, wherein the expression is reduced. A composition comprising one or more siRNAs specific for an antisense oligonucleotide, with a sequence of at least 70% identical sequence to the BRCA2.4 gene. A method of treating a disease associated with the BRCA2 gene, comprising administering to the patient an effective dose of one or more siRNAs specific for the antisense oligonucleotide, with a sequence of at least 70% identical sequence to the BRCA2 gene.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014145911A RU2014145911A (en) | 2014-11-17 | 2014-11-17 | Methods for influencing BRCA2 gene expression |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014145911A RU2014145911A (en) | 2014-11-17 | 2014-11-17 | Methods for influencing BRCA2 gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014145911A true RU2014145911A (en) | 2016-06-10 |
Family
ID=56114787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014145911A RU2014145911A (en) | 2014-11-17 | 2014-11-17 | Methods for influencing BRCA2 gene expression |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2014145911A (en) |
-
2014
- 2014-11-17 RU RU2014145911A patent/RU2014145911A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018006116A (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties. | |
SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
BR112017004349A2 (en) | globin gene therapy for treatment of hemoglobinopathies | |
BR112015023439A2 (en) | combination of cancer treatments using micro-ovens and egfr-tki inhibitors | |
EA201790563A8 (en) | APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY | |
MX2017008462A (en) | Methods of using smad7 antisense oligonucleotides. | |
MX2015012444A (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens. | |
UY35439A (en) | Saline forms of (S) -quinuclidin-3-yl (2-) 2- (2- (4-fluorophenyl) thiazol-4-yl) propan-2-yl) carbamate. | |
BR112018008931A2 (en) | "compounds for treating hypoproliferative disorders" | |
UY35438A (en) | PROCEDURE TO PREPARE INHIBITORS OF GLUCOSILCERAMIDE SINTASA. | |
BR112017011513A2 (en) | treatment of eye conditions using progenitor cells | |
BR112015023260A2 (en) | ozone grain treatment method | |
MY194135A (en) | Treatment and diagnosis of inflammatory disorders | |
RU2014145911A (en) | Methods for influencing BRCA2 gene expression | |
RU2014148877A (en) | Methods for influencing BRCA1 gene expression | |
RU2014145910A (en) | Methods for influencing APOE gene expression | |
RU2014148258A (en) | Methods for influencing ADA gene expression | |
RU2014148879A (en) | Methods for influencing PRP gene expression | |
RU2014142756A (en) | Methods for influencing D4DR gene expression | |
RU2014142757A (en) | Method for influencing TCF gene expression | |
RU2014144701A (en) | Methods for influencing TER1 gene expression | |
RU2014142755A (en) | Methods for influencing CYP17 gene expression | |
RU2014144094A (en) | Methods for influencing CREBBP gene expression | |
RU2014144093A (en) | Methods for influencing CRE gene expression | |
ES2571441A1 (en) | Use of molecules that reduce the levels of lipocalin-2 for the manufacture of a medicine for the treatment of abdominal aortic aneurysm (aaa) (Machine-translation by Google Translate, not legally binding) |